ReviewAPL bioengineering2025
Integrated microfluidic platforms for extracellular vesicles: Separation, detection, and clinical translation.
Review in APL bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Extracellular Vesicles: Classification, Biological Functions, Diseases, and Therapeutic Opportunities.MedComm · 2026Review
- Review
- Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Review
- Uncovering the Intricate and Heterogeneous Cellular Microenvironment of Cutaneous Melanoma.Medicina (Kaunas, Lithuania) · 2026Review
- A plug-and-play surface acoustic wave-based SERS chip for rapid enrichment and ultrasensitive detection of tumor exosomes.Mikrochimica acta · 2026Article
- Mapping the Ischemic Continuum: Dynamic Multi-Omic Biomarker and AI for Personalized Stroke Care.International journal of molecular sciences · 2026Review
- Cell-specific exosomes in sepsis-associated ARDS: from immunometabolic reprogramming to precision medicine.Frontiers in immunology · 2026Review
- Adipose-Derived Stem Cell Exosomes in Diabetic Wound Repair: Molecular Crosstalk, Bioengineering Strategies, and Translational Challenges.Stem cells international · 2026Review
- Advances in the role of extracellular vesicles in circulating microRNA biomarker discovery for lung cancer.Frontiers in cell and developmental biology · 2025Review
- Conditioned Media-Derived Tumor Extracellular Vesicles: Bridging Molecular Insights and Therapeutic Applications in Oncology.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs), secreted by most living cells, encapsulate a diverse array of bioactive molecules from their parent cells, including proteins and nucleic acids. Recent studies underscore the potential of EVs as advanced biomarkers for the early diagnosis of a variety of clinical diseases. Nevertheless, traditional platforms for EVs separation and detection platforms working alone often involve multiple pieces of equipment and complex, multi-step protocols. This extends processing time and the likelihood of bioanalyte loss and cross-contamination, thereby impeding further EVs research. To date, few studies have effectively combined EVs separation, detection, and analysis functions into a single platform. Integrated microfluidic platforms present a compelling solution by enabling seamless progression from sample to result. These platforms can efficiently combine various separation and detection techniques, simplifying complex workflows and facilitating both efficient EVs separation and high-sensitivity detection. This review concentrates on integrated microfluidic platforms for EVs separation and detection, specifically examining whether the separation and detection units are fully integrated. Recent studies underscore the potential of EVs as promising biomarkers for early-stage diagnosis of diseases, including cancer and neurodegenerative disorders. Recent advances in EVs separation and analysis enable overcoming key translational barriers, accelerating their routine adoption in clinical diagnostics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.